Graft Polymer (UK) PLC Updated Investor Presentation (7307N)

TIDMGPL

RNS Number : 7307N

Graft Polymer (UK) PLC

27 September 2023

27 September 2023

Graft Polymer (UK) PLC

("Graft Polymer" or the "Company")

Updated Investor Presentation

Graft Polymer, (LSE:GPL) the speciality multi-sector chemicals company offering modified and alloys polymers and bio-polymer solutions for refiners, compounders and processors, is pleased to announce that an updated Investor Presentation is available today for downloading from the Company's website at www.graftpolymer.com

ENDS

For further information, visit www.graftpolymer.com , follow on Twitter @PolymerLtd or contact:

Graft Polymer (UK) Plc

   Roby Zomer, Non-Executive Chairman                                       Via Flagstaff 

Yifat Steur, CFO and Executive Chairman

Turner Pope Investments Tel:+44 (0) 20 3657 0050

James Pope

Andy Thacker

   Flagstaff Strategic and Investor Communications                    Tel + 44 (0) 207 129 1474 

Tim Thompson [e-mail]

Mark Edwards

Alison Allfrey

Anna Probert

About Graft Polymer

Graft Polymer is a London Stock Exchange listed company (GPL.L) with a cutting-edge, research and development (R&D) and manufacturing facility based in Slovenia which has already introduced more than 50 products to the market. The core business of the Group comprises polymer modification and drug delivery system developments. The Group has developed a proprietary set of polymer modification technologies which uses recycled raw materials and a closed loop system to reduce waste. Graft Polymer's technology can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.

Graft Polymer has three divisions: polymer modification; IP for Bio/Pharma applications including a drug delivery system (Graft Bio) and the Group's food supplement division. A significant milestone was reached in May 2022 when the Slovenian manufacturing facility was granted a Hazard Analysis and Critical Control Point (HACCP) Certificate. The HACCP Certificate allows it to enter the lucrative Business-to-Consumer market and commercialise its IP for Bio/Pharma applications, developing active pharmaceutical ingredients and drug delivery platforms for use in the food supplement market, thereby introducing a further revenue stream to its business.

Environment, Social and Governance is at the forefront of the Group's strategy and the facility in Slovenia has been granted ISO 14001 accreditation in recognition of the environmental management systems in place to reduce waste. Graft Polymer only uses REACH and ROHS certificated raw materials instead of toxic raw materials, and its extensive R&D programme has also developed specialised recycling polymer additives which increases the strength of recycled blends and plastic products whilst also reducing plastic waste by between 40 and 50 per cent.

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCKZGZLKVKGFZM

(END) Dow Jones Newswires

September 27, 2023 02:02 ET (06:02 GMT)